94 results on '"Santana-Davila R"'
Search Results
2. OA12.01 Genomic and Immune Cell Landscape of Response to Chemo-Immunotherapy in Malignant Pleural Mesothelioma
- Author
-
Niknafs, N., primary, Forde, P., additional, Lanis, M., additional, Belcaid, Z., additional, Smith, K., additional, Sun, Z., additional, Balan, A., additional, White, J., additional, Cherry, C., additional, Shivakumar, A., additional, Shao, X., additional, Kindler, H., additional, Purcell, T., additional, Santana-Davila, R., additional, Dudek, A., additional, Borghaei, H., additional, Illei, P., additional, Velculescu, V., additional, Karchin, R., additional, Brahmer, J., additional, Ramalingam, S., additional, and Anagnostou, V., additional
- Published
- 2021
- Full Text
- View/download PDF
3. OA13.01 S1619 A Trial of Neoadjuvant Cisplatin-Pemetrexed With Atezolizumab in Combination and Maintenance for Resectable Pleural Mesothelioma
- Author
-
Tsao, A., primary, Qian, L., additional, Cetnar, J., additional, Sepesi, B., additional, Gomez, D., additional, Wrangle, J., additional, Simon, G., additional, Mott, F., additional, Hall, R., additional, Santana-Davila, R., additional, Koczywas, M., additional, Redman, M., additional, and Kelly, K., additional
- Published
- 2021
- Full Text
- View/download PDF
4. Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q
- Author
-
Chen, D, Hoyer, J D, Ketterling, R P, Tefferi, A, Steensma, D P, Holtan, S G, Santana-Davila, R, Porrata, L F, Dewald, G W, and Hanson, C A
- Published
- 2009
- Full Text
- View/download PDF
5. Genetic aberrations and survival in plasma cell leukemia
- Author
-
Tiedemann, R E, Gonzalez-Paz, N, Kyle, R A, Santana-Davila, R, Price-Troska, T, Van Wier, S A, Chng, W J, Ketterling, R P, Gertz, M A, Henderson, K, Greipp, P R, Dispenzieri, A, Lacy, M Q, Rajkumar, S V, Bergsagel, P L, Stewart, A K, and Fonseca, R
- Published
- 2008
- Full Text
- View/download PDF
6. Ploidy status rarely changes in myeloma patients at disease progression
- Author
-
Chng, W.J., Winkler, J.M., Greipp, P.R., Jalal, S.M., Bergsagel, P.L., Chesi, M., Trendle, M.C., Ahmann, G.J., Henderson, K., Blood, E., Oken, M.M., Hulbert, A., Wier, S.A. Van, Santana-Dávila, R., Kyle, R.A., Gertz, M.A., Lacy, M.Q., Dispenzieri, A., and Fonseca, R.
- Published
- 2006
- Full Text
- View/download PDF
7. OA12.03 Initial Reporting of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC
- Author
-
Skinner, H., primary, Hu, C., additional, Tsakiridis, T., additional, Santana-Davila, R., additional, Lu, B., additional, Erasmus, J., additional, Doemer, A., additional, Videtic, G., additional, Coster, J., additional, Yang, A., additional, Lee, R., additional, Wasik, M. Werner, additional, Schaner, P., additional, Mccormack, S., additional, Esparaz, B., additional, Mcgarry, R., additional, Bazan, J., additional, Stuve, T., additional, and Bradley, J., additional
- Published
- 2019
- Full Text
- View/download PDF
8. P1.14-27 Duration of Targeted Therapy in Advanced NSCLC (aNSCLC) with Drivers Identified by Circulating Tumor DNA (ctDNA) Analysis
- Author
-
Baik, C., primary, Patil, T., additional, Kirtane, K., additional, Santana-Davila, R., additional, Rich, T., additional, Espenschied, C., additional, Weipert, C., additional, Mach, S., additional, Reckamp, K., additional, and Doebele, R., additional
- Published
- 2019
- Full Text
- View/download PDF
9. MA14.07 Phase I Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naïve Non-Small Cell Lung Cancer (JVDF)
- Author
-
Herbst, R., primary, Arkenau, H., additional, Bendell, J., additional, Arrowsmith, E., additional, Wermke, M., additional, Soriano, A., additional, Penel, N., additional, Santana-Davila, R., additional, Bischoff, H., additional, Chau, I., additional, Chao, B., additional, Ferry, D., additional, Mi, G., additional, and Paz-Ares, L., additional
- Published
- 2019
- Full Text
- View/download PDF
10. Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
- Author
-
Chau, I., primary, Bendell, J., additional, Soriano, A., additional, Arkenau, H., additional, Cultrera, J., additional, Santana-Davila, R., additional, Calvo, E., additional, Tourneau, C. Le, additional, Zender, L., additional, Mi, G., additional, Schelman, W., additional, Ferry, D., additional, Herbst, R., additional, and Fuchs, C., additional
- Published
- 2019
- Full Text
- View/download PDF
11. Efficacy and safety of rovalpituzumab tesirine in patients with DLL3-expressing, ≥ 3rd line small cell lung cancer: Results from the phase 2 TRINITY study
- Author
-
Carbone, DP, additional, Morgensztern, D, additional, Le Moulec, S, additional, Santana-Davila, R, additional, Ready, N, additional, Hann, CL, additional, Glisson, BS, additional, Dowlati, A, additional, Rudin, CM, additional, Lally, S, additional, Yalamanchili, S, additional, Wolf, J, additional, Govindan, R, additional, and Besse, B, additional
- Published
- 2019
- Full Text
- View/download PDF
12. RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial
- Author
-
Camidge, D.R., primary, Gadgeel, S.M., additional, Wilkins, H.J., additional, Weems, G., additional, Santana-Davila, R., additional, and Johnson, M., additional
- Published
- 2018
- Full Text
- View/download PDF
13. Outcome Analysis of Treatment in Stage IIA, T3N0 Rectal Adenocarcinoma in the Veterans Health Administration (VHA)
- Author
-
Hall, W.A., primary, Lans, D., additional, Arce-Lara, C., additional, Kelley, M.J., additional, Santana-Davila, R., additional, Marcus, D.M., additional, Tsai, S., additional, Ridolfi, T., additional, Erickson, B.A., additional, and Gore, E.M., additional
- Published
- 2016
- Full Text
- View/download PDF
14. SO-002 - Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
- Author
-
Chau, I., Bendell, J., Soriano, A., Arkenau, H., Cultrera, J., Santana-Davila, R., Calvo, E., Tourneau, C. Le, Zender, L., Mi, G., Schelman, W., Ferry, D., Herbst, R., and Fuchs, C.
- Published
- 2019
- Full Text
- View/download PDF
15. 1169P - RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial
- Author
-
Camidge, D.R., Gadgeel, S.M., Wilkins, H.J., Weems, G., Santana-Davila, R., and Johnson, M.
- Published
- 2018
- Full Text
- View/download PDF
16. P3-13-05: Analysis of Heart Dose-Volume Parameters and Cardiac Events among Node Positive Breast Cancer (NPBC) Patients Treated with Three-Dimensional Conformal Radiation Therapy (3D-CRT).
- Author
-
Bradley, J, primary, Prior, P, additional, Sparks, I, additional, Xiang, Q, additional, Santana-Davila, R, additional, Walker, A, additional, Wilson, JF, additional, Li, XA, additional, and White, J, additional
- Published
- 2011
- Full Text
- View/download PDF
17. Clinicopathological characteristics of subsequent breast cancers in patients with benign breast disease
- Author
-
Santana-Davila, R., primary, Visscher, D. W., additional, Vachon, C. M., additional, Frost, M., additional, Vierkant, R. A., additional, Anderson, S. S., additional, Degnim, A. C., additional, and Hartmann, L. C., additional
- Published
- 2009
- Full Text
- View/download PDF
18. Dysgranulopoiesis is an independent adverse prognostic factor in chronic myeloid disorders with an isolated interstitial deletion of chromosome 5q
- Author
-
Chen, D, primary, Hoyer, J D, additional, Ketterling, R P, additional, Tefferi, A, additional, Steensma, D P, additional, Holtan, S G, additional, Santana-Davila, R, additional, Porrata, L F, additional, Dewald, G W, additional, and Hanson, C A, additional
- Published
- 2008
- Full Text
- View/download PDF
19. Trisomy 13 in patients with hematological malignancies
- Author
-
Santana-Davila, R., primary, Ellliott, M., additional, Hook, C., additional, Kaufmann, S., additional, Letendre, L., additional, Pruthi, R., additional, Tefferi, A., additional, Van Dyke, D., additional, Wiktor, A., additional, and Litzow, M. R., additional
- Published
- 2007
- Full Text
- View/download PDF
20. Natural history of patients with myelodysplastic syndromes (MDS) with interstitial deletions of chromosome 5q detected on G-banded karyotyping
- Author
-
Holtan, S. G., primary, Santana-Davila, R., additional, Dewald, G., additional, Ketterling, R., additional, Tefferi, A., additional, and Steensma, D. P., additional
- Published
- 2007
- Full Text
- View/download PDF
21. Quality of medical education in Mexico.
- Author
-
Santana-Davila R and Martinez C
- Published
- 2004
- Full Text
- View/download PDF
22. Treatment options for patients with triple-negative breast cancer
- Author
-
Perez Edith A and Santana-Davila Rafael
- Subjects
Diseases of the blood and blood-forming organs ,RC633-647.5 ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Breast cancer is a heterogeneous disease composed of different subtypes, characterized by their different clinicopathological characteristics, prognoses and responses to treatment. In the past decade, significant advances have been made in the treatment of breast cancer sensitive to hormonal treatments, as well as in patients whose malignant cells overexpress or amplify HER2. In contrast, mainly due to the lack of molecular targets, little progress has been made in the treatment of patients with triple-negative breast cancer. Recent improved understanding of the natural history, pathophysiology, and molecular features of triple-negative breast cancers have provided new insights into management and therapeutic strategies for women affected with this entity. Ongoing and planned translational clinical trials are likely to optimize and improve treatment of women with this disease.
- Published
- 2010
- Full Text
- View/download PDF
23. Molecular phenotyping of small cell lung cancer using targeted cfDNA profiling of transcriptional regulatory regions.
- Author
-
Hiatt JB, Doebley AL, Arnold HU, Adil M, Sandborg H, Persse TW, Ko M, Wu F, Quintanal Villalonga A, Santana-Davila R, Eaton K, Dive C, Rudin CM, Thomas A, Houghton AM, Ha G, and MacPherson D
- Subjects
- Humans, Regulatory Sequences, Nucleic Acid, Gene Expression Regulation, Neoplastic, Small Cell Lung Carcinoma metabolism, Lung Neoplasms metabolism, Cell-Free Nucleic Acids, Carcinoma, Non-Small-Cell Lung pathology
- Abstract
We report an approach for cancer phenotyping based on targeted sequencing of cell-free DNA (cfDNA) for small cell lung cancer (SCLC). In SCLC, differential activation of transcription factors (TFs), such as ASCL1, NEUROD1, POU2F3, and REST defines molecular subtypes. We designed a targeted capture panel that identifies chromatin organization signatures at 1535 TF binding sites and 13,240 gene transcription start sites and detects exonic mutations in 842 genes. Sequencing of cfDNA from SCLC patient-derived xenograft models captured TF activity and gene expression and revealed individual highly informative loci. Prediction models of ASCL1 and NEUROD1 activity using informative loci achieved areas under the receiver operating characteristic curve (AUCs) from 0.84 to 0.88 in patients with SCLC. As non-SCLC (NSCLC) often transforms to SCLC following targeted therapy, we applied our framework to distinguish NSCLC from SCLC and achieved an AUC of 0.99. Our approach shows promising utility for SCLC subtyping and transformation monitoring, with potential applicability to diverse tumor types.
- Published
- 2024
- Full Text
- View/download PDF
24. Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients.
- Author
-
Chalker C, Voutsinas JM, Wu QV, Santana-Davila R, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, and Rodriguez CP
- Subjects
- Humans, Squamous Cell Carcinoma of Head and Neck drug therapy, Immune Checkpoint Inhibitors adverse effects, Retrospective Studies, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Head and Neck Neoplasms drug therapy, Carcinoma drug therapy
- Abstract
Background: Anti-PD1 checkpoint inhibitors (ICI) represent an established standard-of-care for patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC). Landmark studies excluded patients with ECOG performance status (PS) ≥2; the benefit of ICI in this population is therefore unknown., Methods: We retrospectively reviewed RMHNSCC patients who received 1+ dose of ICI at our institution between 2013 and 2019. Demographic and clinical data were obtained; the latter included objective response (ORR), toxicity, and any unplanned hospitalization (UH). Associations were explored using uni- and multivariate analysis. Overall survival (OS) was estimated using a Cox proportional hazards model; ORR, toxicity, and UH were evaluated with logistic regression., Results: Of the 152 patients, 29 (19%) had an ECOG PS ≥2. Sixty-six (44%) experienced toxicity; 54 (36%) had a UH. A multivariate model for OS containing PS, smoking status, and HPV status demonstrated a strong association between ECOG ≥2 and shorter OS (p < 0.001; HR = 3.30, CI = 2.01-5.41). An association between OS and former (vs. never) smoking was also seen (p < 0.001; HR = 2.17, CI = 1.41-3.35); current smoking did not reach statistical significance. On univariate analysis, poor PS was associated with inferior ORR (p = 0.03; OR = 0.25, CI = 0.06-0.77) and increased UH (p = 0.04; OR = 2.43, CI = 1.05-5.71). There was no significant association between toxicity and any patient characteristic., Conclusions: We observed inferior OS, ORR, and rates of UH among ICI-treated RMHNSCC patients with ECOG 2/3. Our findings help frame discussion of therapeutic options in this poor-risk population., (© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
25. Chemo and Immuno-Therapeutic Options for Nonsmall Cell Lung Cancer Lung Cancer.
- Author
-
Santana-Davila R
- Subjects
- Humans, Immune Checkpoint Inhibitors, Immunotherapy, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Over the last decade, the use of immune checkpoint inhibitors (ICI) has dramatically changed the treatment paradigm and outcome of patients with nonsmall cell lung cancer (NSCLC) across all stages of the disease. In this review, we provide a concise history of the use of ICIs in the treatment of NSCLC and review discuss the data behind the different indications., Competing Interests: Disclosure The author has received honoraria for serving as an advisor for AstraZeneca, Takeda Science Foundation, EMD Sorono, Mirati Therapeutics. The author receive research funding through my institution by Eli Lilly & Co, Genentech, Beyond Spring Pharmaceuticals, ISA Pharmaceuticals, Merck, Pfizer, BMS and ALX oncology., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
26. High End-of-Life Health Care Utilization in a Contemporary Cohort of Head and Neck Cancer Patients Treated with Immune Checkpoint Inhibitors.
- Author
-
Chalker C, Santana-Davila R, Voutsinas JM, Wu QV, Hwang V, Baik CS, Lee S, Barber B, Futran ND, Houlton JJ, Laramore GE, Liao JJ, Parvathaneni U, Martins RG, Eaton KD, and Rodriguez CP
- Subjects
- Death, Humans, Patient Acceptance of Health Care, Retrospective Studies, Head and Neck Neoplasms drug therapy, Immune Checkpoint Inhibitors
- Abstract
Background/Objective: End-of-life health care utilization (EOLHCU) is largely uncharacterized among patients with recurrent/metastatic head and neck squamous cell carcinomas (RMHNSCC), particularly now that immune checkpoint inhibitors (ICI) have been introduced to the treatment landscape. We examined this in a single-institution, retrospective study. Design/Settings: We utilized a database of deceased, ICI-treated RMHNSCC patients to obtain demographic and EOLHCU data, the latter of which included advanced care plan documentation (ACPD) and systemic therapy or emergency room (ER)/hospital/intensive care unit (ICU) admission within 30 days of death (DOD). This was compared with a cohort of deceased thoracic malignancy (TM) patients in an exploratory analysis. Multivariate analysis was performed to examine for association between patient factors (such as age, Eastern Cooperative Oncology Group (ECOG) performance status, or smoking status) and overall survival (OS); associations between the said patient factors and EOLHCU were also evaluated. This study was conducted at an academic, tertiary center in the United States. Results: The RMHNSCC patients ( n = 74) were more likely to have ACPD ( p < 0.01), an emergency department visit ( p < 0.01), and/or hospital admission ( p < 0.01) within 30 DOD relative to the TM group. There was no difference in ICU admissions, ICU deaths, or systemic therapy at end of life (EOL). The OS declined in association with ECOG performance status (PS) and smoking. No association was observed between patient factors and any EOLHCU metric. Conclusions: At our center, patients with ICI-treated RMHNSCC have higher rates of both ACPD and EOLHCU, suggesting high symptom burden and representing opportunities for further study into supportive care augmentation.
- Published
- 2022
- Full Text
- View/download PDF
27. Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
- Author
-
Ganti AKP, Loo BW, Bassetti M, Blakely C, Chiang A, D'Amico TA, D'Avella C, Dowlati A, Downey RJ, Edelman M, Florsheim C, Gold KA, Goldman JW, Grecula JC, Hann C, Iams W, Iyengar P, Kelly K, Khalil M, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran C, Pokharel S, Puri S, Qin A, Rusthoven C, Sands J, Santana-Davila R, Shafique M, Waqar SN, Gregory KM, and Hughes M
- Subjects
- Humans, Medical Oncology, Neoplasm Recurrence, Local, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Lung Neoplasms therapy, Small Cell Lung Carcinoma diagnosis, Small Cell Lung Carcinoma pathology, Small Cell Lung Carcinoma therapy
- Abstract
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Small Cell Lung Cancer (SCLC) provide recommended management for patients with SCLC, including diagnosis, primary treatment, surveillance for relapse, and subsequent treatment. This selection for the journal focuses on metastatic (known as extensive-stage) SCLC, which is more common than limited-stage SCLC. Systemic therapy alone can palliate symptoms and prolong survival in most patients with extensive-stage disease. Smoking cessation counseling and intervention should be strongly promoted in patients with SCLC and other high-grade neuroendocrine carcinomas. The "Summary of the Guidelines Updates" section in the SCLC algorithm outlines the most recent revisions for the 2022 update, which are described in greater detail in this revised Discussion text.
- Published
- 2021
- Full Text
- View/download PDF
28. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
- Author
-
Lakhani NJ, Chow LQM, Gainor JF, LoRusso P, Lee KW, Chung HC, Lee J, Bang YJ, Hodi FS, Kim WS, Santana-Davila R, Fanning P, Squifflet P, Jin F, Kuo TC, Wan HI, Pons J, Randolph SS, and Messersmith WA
- Subjects
- Aged, Antibodies, Monoclonal, Humanized administration & dosage, Female, Follow-Up Studies, Humans, Immunoglobulin Fc Fragments administration & dosage, Male, Maximum Tolerated Dose, Middle Aged, Neoplasms pathology, Prognosis, Trastuzumab administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoplasms drug therapy
- Abstract
Background: Both innate and adaptive immune responses are important components of anticancer immunity. The CD47-SIRPα interaction could represent an important pathway used by tumour cells to evade immune surveillance. We aimed to evaluate the safety, pharmacokinetics, pharmacodynamics, and anticancer activity of evorpacept (also known as ALX148), a high-affinity CD47-blocking protein with an inactive IgG Fc region in patients with solid tumours., Methods: We did a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study at nine hospitals and one clinic in the USA and Korea. Eligible patients for the dose-escalation and safety lead-in phases were aged 18 years or older with histological or cytological diagnosis of advanced or metastatic solid tumours with no available standard therapy, measurable or unmeasurable disease according to the Response Evaluation Criteria in Solid Tumors version 1.1, and an Eastern Cooperative Oncology Group performance status score of 0 or 1. In the dose-escalation phase, which used a 3 + 3 design, patients received intravenous evorpacept at either 0·3, 1, 3, or 10 mg/kg once per week in 21-day cycles, or 30 mg/kg once every other week in 28-day cycles. In the safety lead-in phase, patients were given the maximum tolerable dose of evorpacept from the dose-escalation phase plus either intravenous pembrolizumab (200 mg administered once every 3 weeks) or intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks). In the dose-expansion phase, additional patients aged 18 years or older with second-line or later-line advanced malignancies were enrolled into three parallel cohorts: those with head and neck squamous cell carcinoma (HNSCC) and those with non-small-cell lung cancer (NSCLC) were given the maximum tolerated dose of evorpacept plus intravenous pembrolizumab (200 mg administered once every 3 weeks), and patients with HER2-positive gastric or gastroesophageal junction cancer were given the maximum tolerated dose of evorpacept plus intravenous trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) until disease progression, voluntary withdrawal from the study, or unacceptable toxicity. The primary endpoint was the maximum tolerated dose of evorpacept administered as a single agent and in combination with pembrolizumab or trastuzumab, measured by the occurrence of dose-limiting toxicities during the first cycle, and was assessed in all patients who had received at least one dose of evorpacept. Secondary outcomes included the safety, tolerability, and antitumour activity of evorpacept, alone or in combination with pembrolizumab or trastuzumab. The primary outcome, safety, and tolerability were assessed in all patients who had received at least one dose of evorpacept, and antitumour activity was assessed in those who recieved at least one dose of study treatment and underwent at least one post-baseline tumor assessment. This trial is registered with ClinicalTrials.gov, NCT03013218., Findings: Between March 6, 2017, and Feb 21, 2019, 110 patients received single-agent evorpacept (n=28), evorpacept plus pembrolizumab (n=52), or evorpacept plus trastuzumab (n=30), and were included in the safety analysis. Median follow-up was 29·1 months (95% CI not calculable [NC]-NC) in the single-agent cohort, 27·0 months (25·1-28·8) in the evorpacept plus pembrolizumab cohort, and 32·7 months (27·0-32·7) in the evorpacept plus trastuzumab cohort. Two (7%) dose-limiting toxicities in the first cycle were reported in patients who received single-agent evorpacept; neutropenia with an associated infection in one patient with gastroesophageal junction cancer who received 3 mg/kg once per week, and thrombocytopenia with associated bleeding in one patient with pancreatic cancer who received 30 mg/kg once every other week. No maximum tolerated dose was reached; the maximum administered doses were 10 mg/kg once per week or 30 mg/kg once every other week. The 10 mg/kg once per week dose was used in the expansion cohorts in combination with pembrolizumab or trastuzumab. The most common grade 3 or worse treatment-related adverse events were thrombocytopenia with single-agent evorpacept (two [7%] patients) and evorpacept plus pembrolizumab (two [4%]), and thrombocytopenia (two [7%]) and neutropenia (two [7%]) with evorpacept plus trastuzumab. In patients who received single-agent evorpacept, four treatment-related serious adverse events were reported. Five serious treatment-related adverse events related to evorpacept plus pembrolizumab were reported, and one serious adverse event related to evorpacept plus trastuzumab was reported. In response-evaluable patients in the dose-escalation phase (n=15) receiving single-agent evorpacept once per week, four (27%) had a best overall response of stable disease (two received 0·3 mg/kg, one received 3 mg/kg, and one received 10 mg/kg); in the 11 patients who received single-agent evorpacept at the highest dose of 30 mg/kg once every other week, two (18%) had stable disease. In the dose-expansion cohort, overall responses were recorded in four (20·0%; 95% CI 5·7-43·7) of 20 patients with HNSCC who received evorpacept plus pembrolizumab, in one (5·0%; 0·1-24·9) of 20 patients with NSCLC who received evorpacept plus pembrolizumab, and in four (21·1%; 6·1-45·6) of 19 patients with gastric or gastroesophageal junction cancer who received evorpacept plus trastuzumab., Interpretation: The safety findings support the use of evorpacept in combination with pembrolizumab or trastuzumab for patients with advanced solid tumours. Preliminary antitumour activity results support future investigation of evorpacept combined with pembrolizumab or trastuzumab in patients with HNSCC, gastric or gastroesophageal junction cancer, and NSCLC., Funding: ALX Oncology., Competing Interests: Declaration of interests NJL reports research funding from ALX Oncology, Ascentage, BeiGene, Constellation Pharma, Forty Seven, Alpine, Merck, Pfizer, Regeneron, Apexian, Formation Biologics (Forbius), Symphogen, CytomX, InhibRx, Incyte, Jounce, Livzon, Northern Biologics, Innovent Biologics, Ikena, Odonate, Loxo, Alpine Biosciences, Mersana, Astellas, Celgene, Seagen, Samumed, Sapience Therapeutics, Epizyme, and Mersana; and personal fees from Innovent Biologics, all outside the submitted work. LQMC reports receiving research funding from ALX Oncology; participation on an advisory board for Merck; and receipt of medical writing services from Merck, all outside the submitted work. JFG reports research support from Bristol-Myers Squibb, Tesaro, Moderna, Blueprint, Jounce, Array, Merck, Adaptimmune, Novartis, and ALX Oncology; consulting fees from Genentech-Roche, Bristol-Myers Squibb, Takeda, Loxo-Lilly, Blueprint, Oncorus, Regeneron, Gilead, Moderna, AstraZeneca, EMD Serono, Pfizer, Novartis, Merck, GlydeBio, and Karyopharm; payment or honoraria from Pfizer for lectures, presentations, speakers bureaus, manuscript writing, or educational events; and having a spouse who owns stock and has other ownership interests in Ironwood Pharmaceuticals, all outside the submitted work. PL reports participation on advisory boards or data safety monitoring boards for AbbVie, Agios, Five Prime, GenMab, Halozyme, Roche-Genentech, Genentech, CytomX, Takeda, Cybrexa, Agenus, Tyme, IQVIA, TRIGR, Pfizer, ImmunoMet, Black Diamond, GlaxoSmithKline, QED Therapeutics, AstraZeneca, EMD Serono, Shattuck, Astellas, Salarius, Silverback, MacroGenics, Kyowa Kirin Pharmaceutical Development, Kineta, Zentalis Pharmaceuticals, Molecular Templates, ABL Bio, STCube Pharmaceuticals, Bayer, and I-Mab; and was a consultant for SOTIO, SK Life Science, and I-Mab, all outside the submitted work. K-WL reports research support to their institution from ALX Oncology, AstraZeneca, Ono Pharmaceutical, Merck Sharp & Dohme, Merck, Pfizer, BeiGene, Astellas Pharma, Zymeworks, Five Prime Therapeutics, Macrogenics, Seagen, Bolt Biotherapeutics, Trishula Therapeutics, Oncologie, Pharmacyclics, LSK BioPharma, MedPacto, Green Cross, ABLBIO, Y-BIOLOGICS, Genexine, Daiichi Sankyo, Taiho Pharmaceutical, InvetisBio, Leap Therapeutics; and personal fees from ISU ABXIS, Bayer, Daiichi Sankyo, Bristol-Myers Squibb (consultation), Ono Pharmaceutical, and Boryung Pharmaceutical (honorarium), all outside the submitted work. JL reports receiving consulting fees from Mirati, Seattle Genetics, Oncxerna, and AstraZeneca, all outside the submitted work. Y-JB reports receiving research support paid to their institution from AstraZeneca, Novartis, Genentech-Roche, Merck Sharp & Dohme, Bayer, Merck Serono, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Eli Lilly, Curis, Taiho, Takeda, Ono Pharmaceutical, Daiichi Sankyo, Astellas, BeiGene, Green Cross, and Genexine; and consulting fees from AstraZeneca, Novartis, Genentech-Roche, Merck Sharp & Dohme, Bristol-Myers Squibb, Merck Serono, Daiichi-Sankyo, Astellas, BeiGene, Green Cross, Samyang Biopharm, Hanmi, and ALX Oncology, all outside the submitted work. FSH reports research support to their institution from ALX Oncology, Bristol-Myers Squibb, Novartis, and the National Institutes of Health; consulting fees from Bristol-Myers Squibb, Novartis, EMD Serono, Genentech, Sanofi, Bicara, Apricity, Surface, Compass, Aduro, Pionyr, 7 Hills Pharma, Checkpoint, Bioentre, Gossamer, Iovance, Trillium, Catalym, Immunocore, Amgen, and Rheos; and ownership of stock or stock options in Pionyr, Apricity, Bicara, Checkpoint, and Torque, all outside the submitted work. RS-D reports receiving grants or contracts through his institution from ALX Oncology outside the submitted work. PF reports employment at ALX Oncology, and owning stock or stock options in ALX Oncology. PS is employed by IDDI, and reports research support from ALX Oncology outside the submitted work. FJ reports having a consulting or advisory role at ALX Oncology. HIW reports employment at ALX Oncology, receiving support for travel expenses from ALX Oncology, and owning stock and having other ownership interests in ALX Oncology outside the submitted work. JP reports employment at ALX Oncology, owning stock and having other ownership interests in ALX Oncology, research funding from ALX Oncology, patents planned, issued, or pending at ALX Oncology, and reports a leadership or fiduciary role at Tallac Therapeutics, all outside the submitted work. SSR is employed by and is on the board of directors at ALX Oncology, and reports owning stock and having other ownership interests in ALX Oncology, all outside the submitted work. WAM reports receiving research funding from ALX Oncology outside the submitted work. All other authors declare no competing interests., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
29. Prognostic Value of Early Fluorodeoxyglucose-Positron Emission Tomography Response Imaging and Peripheral Immunologic Biomarkers: Substudy of a Phase II Trial of Risk-Adaptive Chemoradiation for Unresectable Non-Small Cell Lung Cancer.
- Author
-
Bowen SR, Hippe DS, Thomas HM, Sasidharan B, Lampe PD, Baik CS, Eaton KD, Lee S, Martins RG, Santana-Davila R, Chen DL, Kinahan PE, Miyaoka RS, Vesselle HJ, Houghton AM, Rengan R, and Zeng J
- Abstract
Purpose: We sought to examine the prognostic value of fluorodeoxyglucose-positron emission tomography (PET) imaging during chemoradiation for unresectable non-small cell lung cancer for survival and hypothesized that tumor PET response is correlated with peripheral T-cell function., Methods and Materials: Forty-five patients with American Joint Committee on Cancer version 7 stage IIB-IIIB non-small cell lung cancer enrolled in a phase II trial and received platinum-doublet chemotherapy concurrent with 6 weeks of radiation (NCT02773238). Fluorodeoxyglucose-PET was performed before treatment start and after 24 Gy of radiation (week 3). PET response status was prospectively defined by multifactorial radiologic interpretation. PET responders received 60 Gy in 30 fractions, while nonresponders received concomitant boosts to 74 Gy in 30 fractions. Peripheral blood was drawn synchronously with PET imaging, from which germline DNA sequencing, T-cell receptor sequencing, and plasma cytokine analysis were performed., Results: Median follow-up was 18.8 months, 1-year overall survival (OS) 82%, 1-year progression-free survival 53%, and 1-year locoregional control 88%. Higher midtreatment PET total lesion glycolysis was detrimental to OS (1 year 87% vs 63%, P < .001), progression-free survival (1 year 60% vs 26%, P = .044), and locoregional control (1 year 94% vs 65%, P = .012), even after adjustment for clinical/treatment factors. Twenty-nine of 45 patients (64%) were classified as PET responders based on a priori definition. Higher tumor programmed death-ligand 1 expression was correlated with response on PET ( P = .017). Higher T-cell receptor richness and clone distribution slope were associated with improved OS ( P = .018-0.035); clone distribution slope was correlated with PET response ( P = .031)., Conclusions: Midchemoradiation PET imaging is prognostic for survival; PET response may be linked to tumor and peripheral T-cell biomarkers., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
30. Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trial.
- Author
-
Forde PM, Anagnostou V, Sun Z, Dahlberg SE, Kindler HL, Niknafs N, Purcell T, Santana-Davila R, Dudek AZ, Borghaei H, Lanis M, Belcaid Z, Smith KN, Balan A, White JR, Cherry C, Ashok Sivakumar IK, Shao XM, Chan HY, Singh D, Thapa S, Illei PB, Pardoll DM, Karchin R, Velculescu VE, Brahmer JR, and Ramalingam SS
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal adverse effects, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carboplatin therapeutic use, DNA Repair genetics, Female, Genetic Predisposition to Disease genetics, Germ-Line Mutation genetics, Humans, Male, Mesothelioma, Malignant genetics, Mesothelioma, Malignant mortality, Middle Aged, Nucleic Acid Synthesis Inhibitors adverse effects, Pemetrexed adverse effects, Progression-Free Survival, Tumor Suppressor Proteins genetics, Ubiquitin Thiolesterase genetics, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Cisplatin therapeutic use, Mesothelioma, Malignant drug therapy, Nucleic Acid Synthesis Inhibitors therapeutic use, Pemetrexed therapeutic use
- Abstract
Mesothelioma is a rare and fatal cancer with limited therapeutic options until the recent approval of combination immune checkpoint blockade. Here we report the results of the phase 2 PrE0505 trial ( NCT02899195 ) of the anti-PD-L1 antibody durvalumab plus platinum-pemetrexed chemotherapy for 55 patients with previously untreated, unresectable pleural mesothelioma. The primary endpoint was overall survival compared to historical control with cisplatin and pemetrexed chemotherapy; secondary and exploratory endpoints included safety, progression-free survival and biomarkers of response. The combination of durvalumab with chemotherapy met the pre-specified primary endpoint, reaching a median survival of 20.4 months versus 12.1 months with historical control. Treatment-emergent adverse events were consistent with known side effects of chemotherapy, and all adverse events due to immunotherapy were grade 2 or lower. Integrated genomic and immune cell repertoire analyses revealed that a higher immunogenic mutation burden coupled with a more diverse T cell repertoire was linked to favorable clinical outcome. Structural genome-wide analyses showed a higher degree of genomic instability in responding tumors of epithelioid histology. Patients with germline alterations in cancer predisposing genes, especially those involved in DNA repair, were more likely to achieve long-term survival. Our findings indicate that concurrent durvalumab with platinum-based chemotherapy has promising clinical activity and that responses are driven by the complex genomic background of malignant pleural mesothelioma., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
31. Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non-Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial.
- Author
-
Skinner H, Hu C, Tsakiridis T, Santana-Davila R, Lu B, Erasmus JJ, Doemer AJ, Videtic GMM, Coster J, Yang AX, Lee RY, Werner-Wasik M, Schaner PE, McCormack SE, Esparaz BT, McGarry RC, Bazan J, Struve T, Paulus R, and Bradley JD
- Subjects
- Aged, Female, Humans, Male, Middle Aged, Neoplasm Staging, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Non-Small-Cell Lung therapy, Chemoradiotherapy adverse effects, Lung Neoplasms pathology, Lung Neoplasms therapy, Metformin adverse effects
- Abstract
Importance: Non-small cell lung cancer (NSCLC) has relatively poor outcomes. Metformin has significant data supporting its use as an antineoplastic agent., Objective: To compare chemoradiation alone vs chemoradiation and metformin in stage III NSCLC., Design, Setting, and Participants: The NRG-LU001 randomized clinical trial was an open-label, phase 2 study conducted from August 24, 2014, to December 15, 2016. Patients without diabetes who were diagnosed with unresectable stage III NSCLC were stratified by performance status, histology, and stage. The setting was international and multi-institutional. This study examined prespecified endpoints, and data were analyzed on an intent-to-treat basis. Data were analyzed from February 25, 2019, to March 6, 2020., Interventions: Chemoradiation and consolidation chemotherapy with or without metformin., Main Outcomes and Measures: The primary outcome was 1-year progression-free survival (PFS), designed to detect 15% improvement in 1-year PFS from 50% to 65% (hazard ratio [HR], 0.622). Secondary end points included overall survival, time to local-regional recurrence, time to distant metastasis, and toxicity per Common Terminology Criteria for Adverse Events, version 4.03., Results: A total of 170 patients were enrolled, with 167 eligible patients analyzed after exclusions (median age, 64 years [interquartile range, 58-72 years]; 97 men [58.1%]; 137 White patients [82.0%]), with 81 in the control group and 86 in the metformin group. Median follow-up was 27.7 months (range, 0.03-47.21 months) among living patients. One-year PFS rates were 60.4% (95% CI, 48.5%-70.4%) in the control group and 51.3% (95% CI, 39.8%-61.7%) in the metformin group (HR, 1.15; 95% CI, 0.77-1.73; P = .24). Clinical stage was the only factor significantly associated with PFS on multivariable analysis (HR, 1.79; 95% CI, 1.19-2.69; P = .005). One-year overall survival was 80.2% (95% CI, 69.3%-87.6%) in the control group and 80.8% (95% CI, 70.2%-87.9%) in the metformin group. There were no significant differences in local-regional recurrence or distant metastasis at 1 or 2 years. No significant difference in adverse events was observed between treatment groups., Conclusions and Relevance: In this randomized clinical trial, the addition of metformin to concurrent chemoradiation was well tolerated but did not improve survival among patients with unresectable stage III NSCLC., Trial Registration: ClinicalTrials.gov Identifier: NCT02186847.
- Published
- 2021
- Full Text
- View/download PDF
32. Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC.
- Author
-
Herbst RS, Arkenau HT, Bendell J, Arrowsmith E, Wermke M, Soriano A, Penel N, Santana-Davila R, Bischoff H, Chau I, Mi G, Wang H, Rasmussen E, Ferry D, Chao BH, and Paz-Ares L
- Subjects
- Antibodies, Monoclonal, Humanized, B7-H1 Antigen, Humans, Ramucirumab, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy
- Abstract
Introduction: Data of first-line ramucirumab plus pembrolizumab treatment of programmed death-ligand 1 (PD-L1)-positive NSCLC (cohort E) are reported (NCT02443324)., Methods: In this multicenter, open-label phase 1a/b trial, patients received ramucirumab 10 mg/kg and pembrolizumab 200 mg every 21 days for up to 35 cycles. PD-L1 positivity was defined as tumor proportion score (TPS) greater than or equal to 1%. Exploratory NanoString biomarker analyses included three T-cell signatures (T-cell-inflamed, Gajewski, and effector T cells) and CD274 gene expression., Results: Cohort E included 26 patients. Treatment-related adverse events of any grade occurred in 22 patients (84.6%). Treatment-related adverse events of grade greater than or equal to 3 were reported in 11 patients (42.3%); the most frequent was hypertension (n = 4, 15.4%). Objective response rate was 42.3% in the treated population and 56.3% and 22.2% for patients with high (TPS ≥ 50%) and lower levels (TPS 1%-49%) of PD-L1 expression, respectively. Median progression-free survival (PFS) in the treated population was 9.3 months, and 12-month and 18-month PFS rates were 45% each. Median PFS was not reached in patients with PD-L1 TPS greater than or equal to 50% and was 4.2 months in patients with PD-L1 TPS 1% to 49%. Median overall survival was not reached in the treated population, and 12-month and 18-month overall survival rates were 73% and 64%, respectively. Biomarker data suggested a positive association among clinical response, three T-cell signatures, CD274 gene expression, and PD-L1 immunohistochemistry., Conclusions: First-line therapy with ramucirumab plus pembrolizumab has a manageable safety profile in patients with NSCLC, and the efficacy signal seems to be strongest in tumors with high PD-L1 expression., (Copyright © 2020 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. A Phase II study of nab-Paclitaxel (nab-P) in patients with advanced non-small cell lung cancer with EGFR mutations after frontline tyrosine kinase inhibitor therapy.
- Author
-
Baik C, Lee S, Cook K, Wallace S, Wood R, Santana-Davila R, Chow L, Rodriguez C, Eaton KD, and Martins R
- Subjects
- Aged, Aged, 80 and over, Albumins pharmacology, ErbB Receptors metabolism, Female, Humans, Middle Aged, Mutation, Paclitaxel pharmacology, Protein Kinase Inhibitors pharmacology, Albumins therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Paclitaxel therapeutic use, Protein Kinase Inhibitors therapeutic use
- Abstract
Background: Patients with metastatic non-small cell lung cancer (NSCLC) harboring a sensitizing EGFR mutation have effective targeted therapy options initially but most patients eventually progress and receive cytotoxic chemotherapy. In this single-institution phase II study, we evaluated the role of nab-paclitaxel monotherapy in this patient population., Patients and Methods: Patients with metastatic NSCLC with an activating EGFR mutation whose disease progressed after frontline tyrosine kinase inhibitor therapy and who were chemotherapy naïve received nab-paclitaxel 125 mg/m2 on days 1, 8 and 15 in a 28-day cycle. The primary endpoint was response rate per RECIST 1.1 and secondary endpoints were duration of response, progression free survival, toxicity and overall survival., Results: A total of 27 patients were enrolled and 21 patients were evaluable for response. Median age was 65 (range 52-81), 69% of patients were women, 42% of patients did not having a smoking history. 31% of patients had central nervous system (CNS) metastatic disease at baseline. Confirmed partial response was documented in 9 of 26 patients (35%, 95% CI 17-56) and disease control rate was 58% (95% CI 35-73). CNS was a common first site of progression. Median progression free survival was 4.0 months (95% CI 1.8-5.2). No new safety signals were observed., Conclusion: Single agent nab-paclitaxel showed modest antitumor activity in patients with EGFR mutation positive NSCLC and may be an option in patients who are platinum ineligible. Patients often progressed in the CNS and the results underscores the importance of CNS activity of systemic therapies in this patient population., (Copyright © 2021. Published by Elsevier Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
34. Duration of Targeted Therapy in Patients With Advanced Non-small-cell Lung Cancer Identified by Circulating Tumor DNA Analysis.
- Author
-
Reckamp KL, Patil T, Kirtane K, Rich TA, Espenschied CR, Weipert CM, Raymond VM, Santana-Davila R, Doebele RC, and Baik CS
- Subjects
- Adenocarcinoma of Lung drug therapy, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung pathology, Adult, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell genetics, Carcinoma, Squamous Cell pathology, Circulating Tumor DNA analysis, Female, Follow-Up Studies, Humans, Lung Neoplasms drug therapy, Lung Neoplasms genetics, Male, Middle Aged, Prognosis, Retrospective Studies, Survival Rate, Time Factors, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor antagonists & inhibitors, Biomarkers, Tumor genetics, Carcinoma, Non-Small-Cell Lung pathology, Circulating Tumor DNA genetics, Lung Neoplasms pathology, Molecular Targeted Therapy
- Abstract
Background: Outcomes of therapy targeting molecular driver alterations detected in advanced non-small-cell lung (NSCLC) using circulating tumor DNA (ctDNA) have not been widely reported in patients who are targeted therapy-naive., Patients and Methods: We performed a multicenter retrospective review of patients with unresectable stage IIIB to IV NSCLC who received matched therapy after a targetable driver alteration was identified using a commercial ctDNA assay through usual clinical care. Eligible patients must not have received targeted therapy prior to ctDNA testing (prior chemotherapy or immunotherapy was permitted). Kaplan-Meier analysis was used to estimate the median duration of targeted therapy. Patients still on targeted therapy were censored at last follow-up., Results: Seventy-six patients met inclusion criteria. The median age of diagnosis of NSCLC was 64.5 years (range, 31-87 years), 67% were female, 74% were never-smokers, and 97% had adenocarcinoma histology. Twenty-one (28%) patients received systemic treatment prior to targeted therapy, including chemotherapy (n = 17), immunotherapy (n = 5), and/or a biologic (n = 4). Thirty-three (43%) patients remain on targeted therapy at the time of data analysis. The median time on targeted therapy was similar to what has been reported for tissue-detected oncogenic driver mutations in the targeted therapy-naive setting., Conclusions: Patients with ctDNA-detected drivers had durable time on targeted therapy. These treatment outcomes data compliment previous studies that have shown enhanced targetable biomarker discovery rates and high tissue concordance of ctDNA testing when incorporated at initial diagnosis of NSCLC. Identification of NSCLC driver mutations using well-validated ctDNA assays can be used for clinical decision-making and targeted therapy assignment., (Copyright © 2020. Published by Elsevier Inc.)
- Published
- 2020
- Full Text
- View/download PDF
35. Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.
- Author
-
Chau I, Penel N, Soriano AO, Arkenau HT, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Bendell JC, Mi G, Gao L, McNeely SC, Oliveira JM, Ferry D, Herbst RS, and Fuchs CS
- Abstract
Ramucirumab (anti-VEGFR2) plus pembrolizumab (anti-PD1) demonstrated promising antitumor activity and tolerability among patients with previously treated advanced cancers, supporting growing evidence that combination therapies modulating the tumor microenvironment may expand the spectrum of patients who respond to checkpoint inhibitors. Here we present the results of this combination in first-line patients with metastatic G/GEJ cancer. Twenty-eight patients (≥18 years) with no prior systemic chemotherapy in the advanced/metastatic setting received ramucirumab (8 mg/kg days 1 and 8) plus pembrolizumab (200 mg day 1) every 3 weeks as part of JVDF phase 1a/b study. The primary endpoint was safety. Secondary endpoints included progression-free survival (PFS), objective response rate (ORR), and overall survival (OS). Tumors were PD-L1-positive (combined positive score ≥ 1) in 19 and -negative in 6 patients. Eighteen patients experienced grade 3 treatment-related adverse events, most commonly hypertension (14%) and elevated alanine/aspartate aminotransferase (11% each), with no grade 4 or 5 reported. The ORR was 25% (PD-L1-positive, 32%; PD-L1-negative, 17%) with duration of response not reached. PFS was 5.6 months (PD-L1-positive, 8.6 months; PD-L1-negative, 4.3 months), and OS 14.6 months (PD-L1-positive, 17.3 months; PD-L1-negative, 11.3 months). Acknowledging study design limitations, ramucirumab plus pembrolizumab had encouraging durable clinical activity with no unexpected toxicities in treatment-naïve biomarker-unselected metastatic G/GEJ cancer, and improved outcomes in patients with PD-L1-positive tumors.
- Published
- 2020
- Full Text
- View/download PDF
36. A Pilot Study of Atezolizumab Plus Hypofractionated Image Guided Radiation Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.
- Author
-
Qin A, Rengan R, Lee S, Santana-Davila R, Goulart BHL, Martins R, Baik C, Kalemkerian GP, Hassan KA, Schneider BJ, Hayman JA, Jolly S, Hearn J, Lawrence TS, Towlerton AMH, Tewari M, Thomas D, Zhao L, Brown N, Frankel TL, Warren EH, and Ramnath N
- Subjects
- Adult, Aged, Aged, 80 and over, B7-H1 Antigen metabolism, Carcinoma, Non-Small-Cell Lung diagnostic imaging, Carcinoma, Non-Small-Cell Lung pathology, Combined Modality Therapy, Female, Gene Expression Regulation, Neoplastic drug effects, Gene Expression Regulation, Neoplastic radiation effects, Humans, Lung Neoplasms diagnostic imaging, Lung Neoplasms pathology, Male, Middle Aged, Pilot Projects, Safety, Treatment Outcome, Antibodies, Monoclonal, Humanized therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung radiotherapy, Lung Neoplasms drug therapy, Lung Neoplasms radiotherapy, Radiation Dose Hypofractionation, Radiotherapy, Image-Guided
- Abstract
Purpose: Preclinical data and subset analyses from immunotherapy clinical trials indicate that prior radiation therapy was associated with better progression-free survival and overall survival when combined with immune checkpoint inhibitors in patients with non-small cell lung cancer. We present a prospective study of hypofractionated image guided radiation therapy (HIGRT) to a single site of metastatic disease concurrently with atezolizumab in patients with metastatic non-small cell lung cancer., Methods and Materials: Patients meeting eligibility criteria received 1200 mg of atezolizumab intravenously every 3 weeks with concurrent 3- or 5-fraction HIGRT starting no later than the second cycle. The 3-fraction regimen employed a minimum of 8 Gy per fraction compared with 6 Gy for the 5-fraction regimen. Imaging was obtained every 12 weeks to assess response., Results: From October 2015 to February 2017, 12 patients were enrolled in the study (median age 64; range, 55-77 years). The best response by the Response Evaluation in Solid Tumors criteria was partial response in 3 and stable disease in 3, for a disease control rate of 50%. Five patients had a grade 3 immune-related adverse event, including choreoretinitis (n = 1), pneumonitis (n = 1), transaminitis (n = 1), fatigue (n = 1), and peripheral neuropathy (n = 1). The median progression-free survival was 2.3 months, and the median overall survival was 6.9 months (range, 0.4-not reached). There was no clear association between peripheral blood T cell repertoire characteristics at baseline, PD-L1, or tumor mutations and response or outcome. One long-term survivor exhibited oligoclonal T cell populations in a baseline tumor biopsy that were consistently detected in peripheral blood over the entire course of the study., Conclusions: HIGRT plus atezolizumab resulted in an overall response rate of 25% and disease control rate of 50% in this pilot study. The incidence of grade 3 adverse events was similar to that of atezolizumab alone. Alhough it was a pilot study with limited sample size, the results generated hypotheses worthy of further investigation., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
37. Hyperprogressive Disease After Treatment With Checkpoint Inhibitors: Time for Prospective Studies.
- Author
-
Santana-Davila R
- Subjects
- Humans, Immunotherapy, Programmed Cell Death 1 Receptor, Prospective Studies, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms
- Published
- 2020
- Full Text
- View/download PDF
38. A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer.
- Author
-
Rodriguez CP, Wu QV, Voutsinas J, Fromm JR, Jiang X, Pillarisetty VG, Lee SM, Santana-Davila R, Goulart B, Baik CS, Chow LQM, Eaton K, and Martins R
- Subjects
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized administration & dosage, Drug Resistance, Neoplasm, Female, Head and Neck Neoplasms pathology, Humans, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local pathology, Salivary Gland Neoplasms pathology, Squamous Cell Carcinoma of Head and Neck pathology, Survival Rate, Vorinostat administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Head and Neck Neoplasms drug therapy, Neoplasm Recurrence, Local drug therapy, Salivary Gland Neoplasms drug therapy, Squamous Cell Carcinoma of Head and Neck drug therapy
- Abstract
Purpose: This clinical trial combined pembrolizumab and vorinostat in recurrent/metastatic squamous cell carcinomas of the head and neck (HN), and salivary gland cancer (SGC)., Patients and Methods: Patients with progressing incurable HN and SGC, Eastern Cooperative Oncology Group (ECOG) ≤1, no prior immunotherapy, RECIST1.1 measurable disease, and normal organ function were eligible. Pembrolizumab 200 mg was given intravenous every 21 days, and vorinostat 400 mg given orally 5 days on and 2 days off during each 21-day cycle. Primary endpoints were safety and objective response rates., Results: From November 2015 to August 2017, 25 patients with HN and 25 SGC were enrolled. Median age was 61 (range, 33-86) years, 39 (78%) were male, 21 (62%) were never smokers, and 27 (54%) had ECOG 0. In HN, 13 (52%) were p16+ oropharynx. Most common SGC histologies were adenoid cystic 12 (48%), acinic cell 3 (12%), and mucoepidermoid 3 (12%). Adverse events (AEs) in all patients were: 27 (54%) with grade ≥ 1 and 18 (36%) with grade ≥ 3. The most common AEs in all patients were renal insufficiency in seven, (14%), fatigue in six, (12%), and nausea in three (6%). There were three (12%) deaths on study. Responses in HN were complete response (CR) 0, partial response (PR) eight (32%), and stable disease (SD) five (20%). Efficacy in SGCs was CR 0, PR four (16%) in one lymphoepithelioma-like carcinoma, two acinic cell, one adenoid cystic, and SD 14 (56%). In the HN group, median follow-up (mFUP) was 12.6 months, median overall survival (mOS) was 12.6 months, and median progression-free survival (mPFS) was 4.5 months. In SGC, mFUP was 13.1 months, mOS was 14.0 months, and mPFS was 6.9 months., Conclusions: This combination demonstrated activity in HN, with fewer responses in SGC. Toxicities were higher than reported with pembrolizumab alone., (©2019 American Association for Cancer Research.)
- Published
- 2020
- Full Text
- View/download PDF
39. Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study.
- Author
-
Morgensztern D, Besse B, Greillier L, Santana-Davila R, Ready N, Hann CL, Glisson BS, Farago AF, Dowlati A, Rudin CM, Le Moulec S, Lally S, Yalamanchili S, Wolf J, Govindan R, and Carbone DP
- Subjects
- Adult, Aged, Aged, 80 and over, Female, Follow-Up Studies, Humans, Lung Neoplasms metabolism, Lung Neoplasms pathology, Male, Middle Aged, Neoplasm Recurrence, Local metabolism, Neoplasm Recurrence, Local pathology, Prognosis, Small Cell Lung Carcinoma metabolism, Small Cell Lung Carcinoma pathology, Survival Rate, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Benzodiazepinones therapeutic use, Drug Resistance, Neoplasm drug effects, Immunoconjugates therapeutic use, Intracellular Signaling Peptides and Proteins metabolism, Lung Neoplasms drug therapy, Membrane Proteins metabolism, Neoplasm Recurrence, Local drug therapy, Salvage Therapy, Small Cell Lung Carcinoma drug therapy
- Abstract
Purpose: Although extensive-stage small-cell lung cancer (SCLC) is highly responsive to first-line therapy, virtually all patients develop resistance with short survival. Rovalpituzumab tesirine (Rova-T) is an antibody-drug conjugate targeting delta-like 3 protein (DLL3). This open-label, single-arm, phase II study (TRINITY) assessed safety and efficacy of Rova-T in patients with DLL3-expressing SCLC in the third-line and beyond (3L+) setting., Patients and Methods: Patients with DLL3-expressing SCLC (determined by mouse antibody immunohistochemistry [IHC] assay), and ≥2 prior regimens, received 0.3 mg/kg Rova-T once every 6 weeks for two cycles. During study, a rabbit antibody IHC assay was developed and used for the final analysis, with DLL3-positive and DLL3-high defined as ≥25% and ≥75% of tumor cells positive for DLL3, respectively. The primary endpoints were objective response rate (ORR) and overall survival (OS)., Results: Among 339 patients enrolled, 261 (77%) had two prior lines of therapy and 78 (23%) had ≥3. DLL3-high and DLL3-positive tumors by rabbit IHC were seen in 238 (70%) and 287 (85%) patients, respectively. The remaining 52 (15%) were DLL3-negative only by rabbit IHC or had missing results. ORR was 12.4%, 14.3%, and 13.2% in all, DLL3-high, and DLL3-positive patients, respectively. Median OS was 5.6 months in all patients and 5.7 months in DLL3-high patients. The most common adverse events (AE) were fatigue, photosensitivity reaction, and pleural effusion. Grade 3-5 AEs were seen in 213 (63%) patients., Conclusions: Rova-T is the first targeted agent in SCLC to use DLL3, a novel biomarker. However, results demonstrate modest clinical activity in 3L+ SCLC, with associated toxicities., (©2019 American Association for Cancer Research.)
- Published
- 2019
- Full Text
- View/download PDF
40. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
- Author
-
Duma N, Santana-Davila R, and Molina JR
- Subjects
- Carcinoma, Non-Small-Cell Lung epidemiology, Carcinoma, Non-Small-Cell Lung prevention & control, Chemotherapy, Adjuvant, Disease-Free Survival, Education, Medical, Continuing, Female, Humans, Immunotherapy methods, Lung Neoplasms epidemiology, Lung Neoplasms prevention & control, Male, Molecular Targeted Therapy methods, Pneumonectomy methods, Prognosis, Risk Assessment, Survival Analysis, United States, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung therapy, Chemoradiotherapy methods, Early Detection of Cancer methods, Lung Neoplasms diagnosis, Lung Neoplasms therapy
- Abstract
Lung cancer remains the leading cause of cancer deaths in the United States. In the past decade, significant advances have been made in the science of non-small cell lung cancer (NSCLC). Screening has been introduced with the goal of early detection. The National Lung Screening Trial found a lung cancer mortality benefit of 20% and a 6.7% decrease in all-cause mortality with the use of low-dose chest computed tomography in high-risk individuals. The treatment of lung cancer has also evolved with the introduction of several lines of tyrosine kinase inhibitors in patients with EGFR, ALK, ROS1, and NTRK mutations. Similarly, immune checkpoint inhibitors (ICIs) have dramatically changed the landscape of NSCLC treatment. Furthermore, the results of new trials continue to help us understand the role of these novel agents and which patients are more likely to benefit; ICIs are now part of the first-line NSCLC treatment armamentarium as monotherapy, combined with chemotherapy, or after definite chemoradiotherapy in patients with stage III unresectable NSCLC. Expression of programmed cell death protein-ligand 1 in malignant cells has been studied as a potential biomarker for response to ICIs. However, important drawbacks exist that limit its discriminatory potential. Identification of accurate predictive biomarkers beyond programmed cell death protein-ligand 1 expression remains essential to select the most appropriate candidates for ICI therapy. Many questions remain unanswered regarding the proper sequence and combinations of these new agents; however, the field is moving rapidly, and the overall direction is optimistic., (Copyright © 2019 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
41. Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
- Author
-
Herbst RS, Arkenau HT, Santana-Davila R, Calvo E, Paz-Ares L, Cassier PA, Bendell J, Penel N, Krebs MG, Martin-Liberal J, Isambert N, Soriano A, Wermke M, Cultrera J, Gao L, Widau RC, Mi G, Jin J, Ferry D, Fuchs CS, Petrylak DP, and Chau I
- Subjects
- Aged, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents, Immunological adverse effects, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Dose-Response Relationship, Drug, Esophageal Neoplasms drug therapy, Female, Humans, Lung Neoplasms drug therapy, Male, Middle Aged, Stomach Neoplasms drug therapy, Ramucirumab, Adenocarcinoma drug therapy, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Agents, Immunological administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Transitional Cell drug therapy
- Abstract
Background: Pre-clinical and clinical evidence suggests that simultaneous blockade of VEGF receptor-2 (VEGFR-2) and PD-1 or PD-L1 enhances antigen-specific T-cell migration, antitumour activity, and has favourable toxicity. In this study, we aimed to assess the safety and preliminary antitumour activity of ramucirumab (an IgG1 VEGFR-2 antagonist) combined with pembrolizumab (an IgG4 PD-1 antagonist) in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, or urothelial carcinoma., Methods: We did a multicohort, non-randomised, open-label, phase 1a/b trial at 16 academic medical centres, hospitals, and clinics in the USA, France, Germany, Spain, and the UK. We enrolled adult patients aged 18 years or older with histologically confirmed gastric or gastro-oesophageal junction adenocarcinoma (cohorts A and B), non-small-cell lung cancer (cohort C), or urothelial carcinoma (cohort D), whose disease had progressed on one or two lines of previous therapy (for those with gastric or gastro-oesophageal junction adenocarcinoma) or one to three lines of previous therapy (for those with non-small-cell lung cancer and urothelial carcinoma) that included platinum (for all tumour types) or fluoropyrimidine or both (for gastric or gastro-oesophageal junction adenocarcinoma). Eligibility criteria included presence of measurable disease and an Eastern Cooperative Oncology Group performance status of 0-1. Patients with previously untreated gastric or gastro-oesophageal junction adenocarcinoma and non-small-cell lung cancer were also enrolled (in two additional separate cohorts); the results for these cohorts will be reported separately. The first 21-day treatment cycle was a dose-limiting toxicity observation period (phase 1a; safety run-in), followed by a phase 1b cohort expansion stage. Pembrolizumab 200 mg was administered intravenously on day 1, and intravenous ramucirumab was administered at 8 mg/kg on days 1 and 8 for cohort A or at 10 mg/kg on day 1 for cohorts B, C, and D, every 3 weeks, until disease progression or other discontinuation criteria were met. The primary endpoint was the safety and tolerability of ramucirumab in combination with pembrolizumab assessed by the incidence of adverse events in both phase 1a and 1b and as dose-limiting toxicities during phase 1a. The safety and activity analysis set included all patients who received at least one dose of study treatment. This trial is registered with ClinicalTrials.gov, number NCT02443324, and is no longer enrolling patients., Findings: Between July 30, 2015 and June 24, 2016, we enrolled and treated 92 patients (41 with gastric or gastro-oesophageal junction adenocarcinoma, 27 with non-small-cell lung cancer, and 24 with urothelial carcinoma). Median follow-up was 32·8 months (IQR 28·1-33·6). During the first cycle of treatment (phase 1a safety run-in; n=11), one patient with gastro-oesophageal junction adenocarcinoma who received the 8 mg/kg dose of ramucirumab had grade 3 abdominal pain, colitis, hepatitis, interstitial lung disease, and jaundice, and grade 4 cholestasis, and died on treatment on day 40; the death was deemed related to progressive disease. No additional dose-limiting toxicities occurred and the decision was made to maintain the full planned doses of ramucirumab and pembrolizumab in phase 1b (n=81). Treatment-related adverse events occurred in 75 (82%) of 92 patients, the most common of which was fatigue (in 33 patients [36%]), predominantly of grade 1 or 2 severity. 22 patients (24%) had one or more treatment-related adverse events of grade 3 or worse, most commonly hypertension (six patients; 7%) and colitis (five patients; 5%). Serious adverse events occurred in 53 (58%) of 92 patients, and were deemed related to treatment in 22 (24%) patients. The most common treatment-related serious adverse events were abdominal pain in patients with gastric or gastro-oesophageal junction adenocarcinoma (in three [7%] of 41 patients); asthenia and myocardial infarction in patients with non-small-cell lung cancer (two [7%] of 27 patients), and colitis in patients with urothelial carcinoma (two [8%] of 24 patients). Six (7%) of 92 patients discontinued treatment because of treatment-related adverse events, and one death (from pulmonary sepsis in a patient with gastric or gastro-oesophageal junction adenocarcinoma) was deemed related to treatment. The number of patients achieving an objective response was three (7%; 95% CI 1·5-19·9) of 41 in the gastric or gastro-oesophageal junction adenocarcinoma cohort, eight (30%; 13·8-50·2) of 27 in the non-small-cell lung cancer cohort, and three (13%, 2·7-32·4) in the urothelial carcinoma cohort., Interpretation: Ramucirumab in combination with pembrolizumab showed a manageable safety profile with favourable antitumour activity in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma, non-small-cell lung cancer, and urothelial carcinoma. Our results contribute to the growing evidence that supports dual inhibition of the VEGF-VEGFR2 and PD-1-PD-L1 pathways. This combination could be further explored with or without chemotherapy, especially for patients with tumours for which single-agent checkpoint inhibitors have shown no additional benefit over chemotherapy., Funding: Eli Lilly and Company, and Merck and Co., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
42. NCCN Guidelines Insights: Small Cell Lung Cancer, Version 2.2018.
- Author
-
Kalemkerian GP, Loo BW, Akerley W, Attia A, Bassetti M, Boumber Y, Decker R, Dobelbower MC, Dowlati A, Downey RJ, Florsheim C, Ganti AKP, Grecula JC, Gubens MA, Hann CL, Hayman JA, Heist RS, Koczywas M, Merritt RE, Mohindra N, Molina J, Moran CA, Morgensztern D, Pokharel S, Portnoy DC, Rhodes D, Rusthoven C, Sands J, Santana-Davila R, Williams CC, Hoffmann KG, and Hughes M
- Subjects
- Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Brain Neoplasms secondary, Chemoradiotherapy methods, Chemoradiotherapy standards, Cranial Irradiation methods, Cranial Irradiation standards, Dose-Response Relationship, Radiation, Humans, Lung Neoplasms diagnosis, Lung Neoplasms pathology, Medical Oncology methods, Neoplasm Staging, Pneumonectomy methods, Pneumonectomy standards, Radiotherapy Dosage, Randomized Controlled Trials as Topic, Small Cell Lung Carcinoma diagnosis, Small Cell Lung Carcinoma mortality, Small Cell Lung Carcinoma secondary, Societies, Medical standards, Survival Analysis, Treatment Outcome, United States, Brain Neoplasms prevention & control, Lung Neoplasms therapy, Medical Oncology standards, Small Cell Lung Carcinoma therapy
- Abstract
The NCCN Guidelines for Small Cell Lung Cancer (SCLC) address all aspects of disease management. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines for SCLC regarding immunotherapy, systemic therapy, and radiation therapy. For the 2018 update, new sections were added on "Signs and Symptoms of SCLC" and "Principles of Pathologic Review.", (Copyright © 2018 by the National Comprehensive Cancer Network.)
- Published
- 2018
- Full Text
- View/download PDF
43. Head and Neck Cancer in Elderly Patients: What to Do When Data Are Limited?
- Author
-
Santana-Davila R
- Subjects
- Aged, Humans, Head and Neck Neoplasms
- Published
- 2018
- Full Text
- View/download PDF
44. Racial disparity in oncologic and quality-of-life outcomes in patients with locally advanced head and neck squamous cell carcinomas enrolled in a randomized phase 2 trial.
- Author
-
Guerriero MK, Redman MW, Baker KK, Martins RG, Eaton K, Chow LQ, Santana-Davila R, Baik C, Goulart BH, Lee S, and Rodriguez CP
- Subjects
- Adult, Aged, Antineoplastic Agents administration & dosage, Antineoplastic Agents adverse effects, Chemoradiotherapy methods, Cisplatin administration & dosage, Cisplatin adverse effects, Erlotinib Hydrochloride administration & dosage, Erlotinib Hydrochloride adverse effects, Female, Head and Neck Neoplasms ethnology, Head and Neck Neoplasms mortality, Humans, Male, Middle Aged, Racial Groups statistics & numerical data, Response Evaluation Criteria in Solid Tumors, Squamous Cell Carcinoma of Head and Neck ethnology, Squamous Cell Carcinoma of Head and Neck mortality, Survival Analysis, Chemoradiotherapy adverse effects, Head and Neck Neoplasms therapy, Health Status Disparities, Quality of Life, Squamous Cell Carcinoma of Head and Neck therapy
- Abstract
Background: To better understand patient-reported quality of life (PRQOL) for patients with head and neck cancer, PRQOL scores were collected in a clinical trial., Methods: Patients were randomized to arm A (70 Gy of radiation with cisplatin) or arm B (70 Gy of radiation with cisplatin plus erlotinib at 150 mg daily). PRQOL scores were measured on days -7 (arm B only), 0, 30, and 180 with the University of Washington Quality of Life Questionnaire. Associations with clinical factors and outcomes were explored with linear mixed, logistic, and Cox regression models., Results: One hundred eighty-nine patients (97 in arm A and 92 in arm B) consented to PRQOL collection. Patients were balanced apart from more females in arm A (20 [21%] vs 8 [9%]; P = .02). There were 17 black patients (18%) in arm A and 12 (13%) in arm B (P = .39). There was no change in the mean scores in arm B from day -7 to day 0 (P = .36). Scores were lower in both arms at day 30 (P for both < .0001), with no difference by arm (P = .10). Scores on day 180 remained lower for arm A (-6.79; 95% confidence interval [CI], -12.6 to -1.0; P = .02). In arm B, this difference was not significant, and this suggested that the scores had returned to the baseline by day 180 (P = .73). After adjustments for potential confounders, black race was an independent predictor for inferior scores (-11.4; 95% CI, -16.84 to -5.94; P < .0001), complete response rates (odds ratio, 0.34; 95% CI, 0.12-0.91; P = .03), and overall survival (hazard ratio, 3.71; 95% CI, 1.63-8.47; P < .01)., Conclusions: PRQOL scores predictably worsened during and improved after chemoradiation. Black patients had inferior PRQOL and overall survival. Cancer 2018;124:2841-2849. © 2018 American Cancer Society., (© 2018 American Cancer Society.)
- Published
- 2018
- Full Text
- View/download PDF
45. A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma.
- Author
-
Méndez E, Rodriguez CP, Kao MC, Raju S, Diab A, Harbison RA, Konnick EQ, Mugundu GM, Santana-Davila R, Martins R, Futran ND, and Chow LQM
- Subjects
- Antineoplastic Combined Chemotherapy Protocols adverse effects, Biomarkers, Biopsy, Cisplatin administration & dosage, Cisplatin pharmacokinetics, Docetaxel administration & dosage, Docetaxel pharmacokinetics, Drug Administration Schedule, Female, Gene Expression Profiling, Genomics methods, Humans, Male, Neoadjuvant Therapy, Positron-Emission Tomography, Pyrazoles administration & dosage, Pyrazoles pharmacokinetics, Pyrimidinones administration & dosage, Pyrimidinones pharmacokinetics, Squamous Cell Carcinoma of Head and Neck diagnosis, Squamous Cell Carcinoma of Head and Neck genetics, Squamous Cell Carcinoma of Head and Neck mortality, Treatment Outcome, Tumor Burden, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Squamous Cell Carcinoma of Head and Neck drug therapy
- Abstract
Purpose: The WEE1 tyrosine kinase regulates G
2 -M transition and maintains genomic stability, particularly in p53-deficient tumors which require DNA repair after genotoxic therapy. Thus, a need arises to exploit the role of WEE1 inhibition in head and neck squamous cell carcinoma (HNSCC) mostly driven by tumor-suppressor loss. This completed phase I clinical trial represents the first published clinical experience using the WEE1 inhibitor, AZD1775, with cisplatin and docetaxel. Patients and Methods: We implemented an open-label phase I clinical trial using a 3+3 dose-escalation design for patients with stage III/IVB HNSCC with borderline-resectable or -unresectable disease, but who were candidates for definitive chemoradiation. Escalating AZD1775 was administered orally twice a day over 2.5 days on the first week, then in combination with fixed cisplatin (25 mg/m2 ) and docetaxel (35 mg/m2 ) for 3 additional weeks. The primary outcome measure was adverse events to establish MTD. Secondary measures included response rates, pharmacokinetics (PK), pharmacodynamics, and genomic data. Results: The MTD for AZD1775 was established at 150 mg orally twice per day for 2.5 days. RECISTv1.1 responses were seen in 5 of 10 patients; histologic adjustment revealed three additional responders. The only drug-limiting toxicity was grade 3 diarrhea. The PK C8hr target of 240 nmol/L was achieved on day 4 at all three doses tested. Pharmacodynamic analysis revealed a reduction in pY15-Cdk, and increases in γH2AX, CC3, and RPA32/RPA2 were noted in responders versus nonresponders. Conclusions: The triplet combination of AZD1775, cisplatin, and docetaxel is safe and tolerable. Preliminary results show promising antitumor efficacy in advanced HNSCC, meriting further investigation at the recommended phase II dose. Clin Cancer Res; 24(12); 2740-8. ©2018 AACR ., (©2018 American Association for Cancer Research.)- Published
- 2018
- Full Text
- View/download PDF
46. Phase II trial of eribulin mesylate in recurrent or metastatic salivary gland malignancies.
- Author
-
Rodriguez CP, Martins RG, Baik C, Chow LQ, Santana-Davila R, Goulart BH, Lee S, and Eaton KD
- Subjects
- Adult, Aged, Antineoplastic Agents adverse effects, Female, Furans adverse effects, Humans, Ketones adverse effects, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Salivary Gland Neoplasms pathology, Treatment Outcome, Antineoplastic Agents therapeutic use, Furans therapeutic use, Ketones therapeutic use, Salivary Gland Neoplasms drug therapy
- Abstract
Background: This study examined the microtubule inhibitor eribulin in recurrent/metastatic salivary gland cancers (RMSGCs), a disease where no therapeutic standard exists., Methods: This phase II clinical trial treated patients with progressive recurrent/metastatic salivary gland cancers with eribulin 1.4 mg/m
2 i.v. on days 1 and 8 of a 21-day cycle until disease progression/unacceptable toxicities. The primary endpoint was the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 objective response rate., Results: Between May 2012 and August 2015, 29 patients were enrolled in this study. The median age was 63 years (range 34-75 years) and 20 of the subjects were men (69%). The most common histologies were adenoid cystic carcinoma (ACC; n = 11) and adenocarcinoma (n = 4). Neutropenia was the most common toxicity (grade 3; n = 5; 17% and grade 4 n = 3; 10%). The objective responses were observed in 3 of 29 patients (10%), 20 of 29 patients (69%) demonstrated a decrement in tumor size, and disease control was observed in 26 of 29 patients (90%)., Conclusion: Although the objective responses to eribulin were uncommon, disease control was observed in the majority of patients., (© 2017 Wiley Periodicals, Inc.)- Published
- 2018
- Full Text
- View/download PDF
47. Immunotherapy for Head and Neck Cancer in the Era of Exponentially Increasing Health Care Expenditure.
- Author
-
Santana-Davila R and Rodriguez CP
- Subjects
- Cost-Benefit Analysis, Health Expenditures, Humans, Immunotherapy, Neoplasm Recurrence, Local, Nivolumab, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck
- Abstract
Competing Interests: Disclosures of potential conflicts of interest may be found at the end of this article.
- Published
- 2018
- Full Text
- View/download PDF
48. The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer.
- Author
-
Santana-Davila R and Chow LQ
- Subjects
- Antineoplastic Agents, Immunological therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung immunology, Carcinoma, Non-Small-Cell Lung mortality, Carcinoma, Non-Small-Cell Lung pathology, Clinical Trials as Topic, Combined Modality Therapy, Humans, Immunomodulation drug effects, Lung Neoplasms immunology, Lung Neoplasms mortality, Lung Neoplasms pathology, Molecular Targeted Therapy, Treatment Outcome, Carcinoma, Non-Small-Cell Lung therapy, Immunotherapy adverse effects, Immunotherapy methods, Lung Neoplasms therapy
- Published
- 2018
- Full Text
- View/download PDF
49. Predictors of outcome with cetuximab and paclitaxel for head and neck squamous cell carcinoma.
- Author
-
Pellini Ferreira B, Redman M, Baker KK, Martins R, Eaton KD, Chow LQM, Baik CS, Goulart B, Lee SM, Santana-Davila R, and Rodriguez CP
- Subjects
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols adverse effects, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell pathology, Cetuximab adverse effects, Disease-Free Survival, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Male, Middle Aged, Neoplasm Recurrence, Local drug therapy, Neoplasm Recurrence, Local pathology, Otorhinolaryngologic Neoplasms mortality, Paclitaxel adverse effects, Prognosis, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Carcinoma, Squamous Cell drug therapy, Cetuximab administration & dosage, Otorhinolaryngologic Neoplasms drug therapy, Paclitaxel administration & dosage
- Abstract
Objectives: Identify predictors of outcome in patients with recurrent/metastatic head and neck squamous cell carcinoma (RMHNSCC) treated with weekly cetuximab and paclitaxel (CP)., Study Design: Retrospective analysis., Methods: Patients with RMHNSCC treated with CP were identified and patient data was recorded. The Kaplan-Meier method was used to estimate outcomes, and Cox regression analysis was used to examine outcome predictors., Results: Fifty-nine patients initiated CP between January 2007 and June 2014. Median age was 56 (range: 39-80) years. The most common primary sites were the oropharynx in 22 (37%) patients, oral cavity in 19 (32%), and larynx in 11 (19%). Eastern Cooperative Oncology Group performance status (ECOG PS) was 0 in seven (12%), 1 in 32 (54%), and 2 in 16 (28%) patients. In 44 (75%) patients, CP was used as a first-line R/M regimen. Median number of cycles was five (range: 1-29). Dose modifications were necessary in 27 (46%) patients. The objective response rate was 47.5%, with 27 (45.8%) partial responses and one (2%) complete response. With a median follow-up of 13.4 months, median progression-free (PFS) and overall survival (OS) were 7.7 and 13.2 months, respectively. On multivariable analysis, an ECOG of 2 of 3 was associated with inferior OS (hazard ratio [HR]: 3.94; P = 0.01; 95% confidence interval [CI]: 1.1-14.04) and PFS (HR: 7.29; P < 0.01; 95% CI: 2.1-26.0) compared to an ECOG 0 of 1. First-line CP administration was associated with superior PFS compared to second line (HR: 2.6; P = 0.02; 95% CI:1.2-5.5)., Conclusions: CP is well tolerated in this population of patients, with favorable tumor efficacy. First-line use and an ECOG 0 of 1 points appears to confer superior outcomes., Level of Evidence: 4. Laryngoscope, 127:1583-1588, 2017., (© 2016 The American Laryngological, Rhinological and Otological Society, Inc.)
- Published
- 2017
- Full Text
- View/download PDF
50. A phase I study of pazopanib in combination with escalating doses of 131I in patients with well-differentiated thyroid carcinoma borderline refractory to radioiodine.
- Author
-
Chow LQ, Santana-Davila R, Pantel A, Roth M, Anderson LN, Failor A, Doot R, and Mankoff D
- Subjects
- Adult, Aged, Combined Modality Therapy, Female, Humans, Indazoles, Male, Middle Aged, Pyrimidines administration & dosage, Sulfonamides administration & dosage, Antineoplastic Agents therapeutic use, Iodine Radioisotopes administration & dosage, Pyrimidines therapeutic use, Sulfonamides therapeutic use, Thyroid Neoplasms drug therapy, Thyroid Neoplasms radiotherapy
- Abstract
Objective: This trial was conducted to evaluate the ability of pazopanib to overcome therapeutic 131I resistance., Materials, Methods and Patients: This phase 1 trial assesses the combination of pazopanib and escalating doses of radioiodine (131I) in patients with recurrent or metastatic thyroid cancer that are borderline or relatively iodine refractory. Radioiodine uptake scans were assessed post therapy and compared to historical pre-treatment scans. Patients underwent FDG PET/CT before and after the initial pazopanib treatment to identify the impact of pazopanib on the cancer prior to 131I therapy., Results: A dose limiting toxicity (cardiac arrhythmia and grade 3 fatigue) in the first patient in the first cohort prompted expansion to a total of 6 patients. Additional grade 3-4 hematologic toxicity and low accrual in the expanded cohort led to the decision not to pursue further study of the regimen. In patients with measurable disease 4/5 (80%) achieved stable disease. Median progression free survival was 6.7 months. At 3 years of follow up, one patient died due to progressive disease, two are being treated with systemic therapy and 3 continue without requiring subsequent therapy at 15, 27 and 35 months from the last dose of pazopanib. There was no convincing impact of pazopanib on iodine uptake in scans performed pre- and post-therapy compared to scans from historical 131I treatments without pazopanib., Conclusion: Despite a suggestion of therapeutic efficacy, combined pazopanib and 131I resulted in increased toxicity. There was no convincing evidence that the administration of pazopanib improved iodine uptake or retention., Trial Registration: ClinicalTrials.gov NCT01413113.
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.